Somewhat Positive News Coverage Very Unlikely to Impact AstraZeneca (NYSE:AZN) Stock Price

Share on StockTwits

Media coverage about AstraZeneca (NYSE:AZN) has trended somewhat positive recently, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than 6,000 blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a news sentiment score of 1.52 on their scale. InfoTrie also assigned media stories about the company an news buzz score of 2 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have impacted AstraZeneca’s analysis:

Shares of NYSE:AZN opened at $55.22 on Friday. The company has a market capitalization of $145.08 billion, a PE ratio of 93.59, a price-to-earnings-growth ratio of 1.68 and a beta of 0.56. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.75 and a quick ratio of 0.57. The business has a fifty day moving average price of $50.01 and a two-hundred day moving average price of $48.29. AstraZeneca has a 1 year low of $36.15 and a 1 year high of $57.44.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.06. The firm had revenue of $6.35 billion during the quarter, compared to the consensus estimate of $5.95 billion. AstraZeneca had a return on equity of 33.97% and a net margin of 5.94%. The business’s revenue for the quarter was up 16.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. Sell-side analysts anticipate that AstraZeneca will post 2.01 earnings per share for the current year.

Several equities research analysts recently issued reports on the company. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Monday, April 27th. Morgan Stanley reiterated an “equal weight” rating on shares of AstraZeneca in a report on Wednesday, May 6th. ValuEngine upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. Cowen reiterated a “buy” rating and set a $55.00 price target on shares of AstraZeneca in a report on Friday, February 28th. Finally, Argus upped their price target on AstraZeneca from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and a consensus price target of $54.67.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: What is Elliott Wave theory?

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Eagle Asset Management Inc. Has $662,000 Stake in Mitsubishi UFJ Financial Group Inc
Eagle Asset Management Inc. Has $662,000 Stake in Mitsubishi UFJ Financial Group Inc
Research Analysts Offer Predictions for Tempur Sealy International Inc’s FY2020 Earnings
Research Analysts Offer Predictions for Tempur Sealy International Inc’s FY2020 Earnings
Orchard Therapeutics PLC –  Shares Purchased by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.
Orchard Therapeutics PLC – Shares Purchased by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.
Ensign Peak Advisors Inc Grows Stock Holdings in Integra Lifesciences Holdings Corp
Ensign Peak Advisors Inc Grows Stock Holdings in Integra Lifesciences Holdings Corp
Universal Health Realty Income Trust  Shares Purchased by Virginia Retirement Systems ET AL
Universal Health Realty Income Trust Shares Purchased by Virginia Retirement Systems ET AL
Virginia Retirement Systems ET AL Has $797,000 Stock Position in Third Point Reinsurance Ltd
Virginia Retirement Systems ET AL Has $797,000 Stock Position in Third Point Reinsurance Ltd


© 2006-2020 Ticker Report